SCHEMBL21302002

SCHEMBL21302002

CC(C)(C)OC(=O)N1CCN(c2cccc(NCc3ccc(Cl)c(Cl)c3)c2[N+](=O)[O-])CC1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MET P08581 2/20 0.48
MAPK8 P45983 1/20 0.45
MAPT P10636 2/20 0.45
ALDH1A1 P00352 1/20 0.45
LMNA P02545 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.42
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
KCNH2 Q12809 1/20 0.42
ACHE P22303 1/20 0.42
CCNT1 O60563 1/20 0.41
KDM1A O60341 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
TACR1 P25103 1/20 0.40
KCNQ2 O43526 1/20 0.40
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30516373 1.00 MET (0.48) METMAPK8MAPTALDH1A1LMNA
SCHEMBL31066775 1.00 MET (0.48) METMAPK8MAPTALDH1A1LMNA
SCHEMBL21301976 0.92 MET (0.48) METMAPK8MAPTALDH1A1LMNA
SCHEMBL31066776 0.92 MET (0.48) METMAPK8MAPTALDH1A1LMNA
SCHEMBL31066761 0.90 MET (0.51) METMAPK8MAPTALDH1A1LMNA
SCHEMBL22712827 0.90 MET (0.51) METMAPK8MAPTALDH1A1LMNA
SCHEMBL30516389 0.90 MET (0.51) METMAPK8MAPTALDH1A1LMNA
SCHEMBL21301989 0.89 MET (0.48) METMAPK8MAPTALDH1A1LMNA
SCHEMBL30516385 0.89 MET (0.48) METMAPK8MAPTALDH1A1LMNA
SCHEMBL21301973 0.88 MET (0.50) METMAPK8MAPTALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11981668-B2 Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists ADAMED PHARMA S.A. (PL) 2024-05-14 US disclosed
EP-3755688-B1 INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS ADAMED PHARMA S A (PL) 2023-06-14 EP disclosed
EP-3755688-B1 INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS ADAMED PHARMA S A (PL) 2023-06-14 EP disclosed
US-20210276995-A1 INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS ADAMED PHARMA S.A. (PL) 2021-09-09 US disclosed
US-20210276995-A1 INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS ADAMED PHARMA S.A. (PL) 2021-09-09 US disclosed
US-11034688-B2 Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists ADAMED PHARMA S.A. (PL) 2021-06-15 US disclosed
US-11034688-B2 Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists ADAMED PHARMA S.A. (PL) 2021-06-15 US disclosed
CN-112041300-A Indole and benzimidazole derivatives as dual 5-HT2A and5-HT 6receptor antagonists 阿达梅德制药公司 2020-12-04 CN disclosed
US-20200377496-A1 INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A and 5-HT6 RECEPTOR ANTAGONISTS ACADIA PHARMACEUTICALS INC. 2020-12-03 US disclosed
US-20200377496-A1 INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A and 5-HT6 RECEPTOR ANTAGONISTS ACADIA PHARMACEUTICALS INC. 2020-12-03 US disclosed
WO-2019162306-A1 INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS ADAMED PHARMA S.A. (PL) 2019-08-29 WO disclosed
EP-3530651-A1 INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS Adamed sp. z o.o. (PL) 2019-08-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11981668-B2 Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists HTR2A, HTR2C, HTR6 MET 1905/4885MAPK8 4552/4885MAPT 228/4885
US-11034688-B2 Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists HTR2A, HTR6, HTR2C MET 2102/4885MAPK8 4595/4885MAPT 338/4885
US-20200377496-A1 INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A and 5-HT6 RECEPTOR ANTAGONISTS HTR2A, HTR6, HTR2C MET 2102/4885MAPK8 4595/4885MAPT 338/4885
US-20210276995-A1 INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS HTR2A, HTR2C, HTR6 MET 1905/4885MAPK8 4552/4885MAPT 228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.